Compare GORO & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GORO | ELDN |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.3M | 120.8M |
| IPO Year | N/A | N/A |
| Metric | GORO | ELDN |
|---|---|---|
| Price | $0.73 | $1.48 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $1.38 | ★ $11.00 |
| AVG Volume (30 Days) | 1.2M | ★ 4.0M |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $61,430,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $117.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.16 | $1.35 |
| 52 Week High | $1.18 | $5.08 |
| Indicator | GORO | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 50.55 | 31.96 |
| Support Level | $0.62 | $1.54 |
| Resistance Level | $0.83 | $1.68 |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 52.29 | 22.41 |
Gold Resource Corp is a producer of metal concentrates that contain gold, silver, copper, lead, and zinc in Oaxaca, Mexico. . It targets low capital expenditure projects with the potential for generating high returns on capital. The company's two pipeline projects are; Don David Gold at Oaxaca, Mexico, and Back Forty at Michigan, United States of America. The Company has two reporting segments, based on geographic regions. Oaxaca, Mexico represents the Company's only operating segment with a production stage property. The Company's other reporting segment is Michigan, U.S.A., with an exploration stage property.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.